- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03775187
Expanded Access to Burosumab
February 28, 2025 updated by: Kyowa Kirin Co., Ltd.
Individual patient expanded access requests may be considered for patients who have no other treatment options
Study Overview
Status
Available
Intervention / Treatment
Detailed Description
Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies.
For full details, please visit the links provided below.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
December 11, 2018
First Submitted That Met QC Criteria
December 11, 2018
First Posted (Actual)
December 13, 2018
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 28, 2025
Last Verified
September 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Bone Diseases
- Musculoskeletal Diseases
- Nutrition Disorders
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Bone Diseases, Metabolic
- Phosphorus Metabolism Disorders
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Metal Metabolism, Inborn Errors
- Rickets, Hypophosphatemic
- Rickets
- Hypophosphatemia, Familial
- Renal Tubular Transport, Inborn Errors
- Calcium Metabolism Disorders
- Vitamin D Deficiency
- Hypophosphatemia
- Familial Hypophosphatemic Rickets
- Osteomalacia
Other Study ID Numbers
- UX023-EAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on X-linked Hypophosphatemia
-
Yale UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedHypophosphatemic Rickets, X Linked DominantUnited States
-
Kyowa Kirin Pharmaceutical Development LtdActive, not recruitingX-Linked HypophosphatemiaSpain, Italy, United Kingdom, France, Belgium, Denmark, Germany, Hungary, Portugal, Norway, Switzerland, Israel, Netherlands, Czechia, Bulgaria, Sweden, Slovenia, Ireland, Latvia, Slovakia
-
Kyowa Kirin Co., Ltd.Active, not recruiting
-
Wuerzburg University HospitalKyowa Kirin, Inc.Active, not recruiting
-
Kyowa Kirin Co., Ltd.CompletedX-linked Hypophosphatemia (XLH)China
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaUnited States
-
Kyowa Kirin Pharmaceutical Development LtdCompletedX-Linked HypophosphatemiaFrance, United Kingdom, Spain, Germany, Netherlands
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaKorea, Republic of, Canada, United States, Australia, Japan, United Kingdom, Sweden
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingX-linked Hypophosphatemia (XLH)
-
Kyowa Kirin Pharmaceutical Development LtdCompletedX-linked Hypophosphatemia (XLH)Sweden, Spain, United Kingdom, Italy, Austria, France
Clinical Trials on Burosumab
-
Kyowa Kirin Pharmaceutical Development LtdCompletedX-Linked HypophosphatemiaFrance, United Kingdom, Spain, Germany, Netherlands
-
National Institute of Dental and Craniofacial Research...CompletedFibrous Dysplasia Of BoneUnited States
-
Wuerzburg University HospitalKyowa Kirin, Inc.Completed
-
Redwood Dermatology SciencesUltragenyx Pharmaceutical IncCompletedPain, Chronic | Hypophosphatemia | Hypophosphatemic RicketsUnited States
-
Bicetre HospitalUnknownRare Diseases | X-linked HypophosphatemiaFrance
-
Laura TosiChildren's National Research Institute; Ultragenyx Pharmaceutical IncActive, not recruitingCutaneous Skeletal Hypophosphatemia Syndrome (CSHS) | Epidermal Nevus SyndromeUnited States
-
Kyowa Kirin Pharmaceutical Development LtdCompletedX-linked HypophosphatemiaUnited Kingdom, France, Ireland, Italy
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaUnited States
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-linked HypophosphatemiaUnited States, Korea, Republic of, Japan, Ireland, United Kingdom, France, Italy
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-linked HypophosphatemiaNetherlands, United States, United Kingdom, France